Literature DB >> 8347460

Use of positron emission tomography in oncology.

J A Glaspy1, R Hawkins, C K Hoh, M E Phelps.   

Abstract

Positron emission tomography is an imaging technique that produces images reflective of tissue biochemistry rather than anatomy. Utilizing different isotopes, many biochemical processes can be studied repetitively and non-invasively in cancers in vivo. Malignant tissue is characterized by an accelerated rate of glycolysis. This biochemical characteristic of malignancy can be exploited by PET imaging with the radiopharmaceutical FDG. PET with FDG has been successful in imaging primary and metastatic cancer of the breast, colon, lung, head and neck, as well as sarcomas and lymphomas. PET FDG imaging has potential as a screening, diagnostic and staging tool in cancer. Recently, whole body PET techniques have been developed which permit imaging of the entire body during a single scanning session. PET also has tremendous potential as a cancer research tool to study serial estimates of tumor glycolysis, DNA turnover, oxygen metabolism, protein synthesis, and blood.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8347460

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  8 in total

Review 1.  Positron emission tomography (PET) in the evaluation of patients with cancer.

Authors:  H A Godwin; J H Zuger
Journal:  Trans Am Clin Climatol Assoc       Date:  1999

Review 2.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

3.  Early colon cancer detected by 18F-FDG PET.

Authors:  Kazuhiro Sakamoto; Makoto Takahashi; Yukihiro Yaginuma; Yasunori Ishido; Takashi Matsuoka; Shuichi Sakamoto; Yuichi Tomiki; Toshiki Kamano
Journal:  Int J Gastrointest Cancer       Date:  2005

4.  Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability.

Authors:  K Scheidhauer; A Scharl; U Pietrzyk; R Wagner; U J Göhring; K Schomäcker; H Schicha
Journal:  Eur J Nucl Med       Date:  1996-06

5.  Pilot Prospective Evaluation of (18)F-Alfatide II for Detection of Skeletal Metastases.

Authors:  Baoming Mi; Chunjing Yu; Donghui Pan; Min Yang; Weixing Wan; Gang Niu; Xiaoyuan Chen
Journal:  Theranostics       Date:  2015-07-12       Impact factor: 11.556

Review 6.  Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors.

Authors:  Li Li; Xiaoyuan Chen; Jinming Yu; Shuanghu Yuan
Journal:  Front Oncol       Date:  2022-03-02       Impact factor: 6.244

7.  Use of FDG-PET in differentiating benign from malignant compression fractures.

Authors:  Miriam A Bredella; Brendan Essary; Martin Torriani; Hugue A Ouellette; William E Palmer
Journal:  Skeletal Radiol       Date:  2008-02-16       Impact factor: 2.199

8.  A rare occurrence of a malignant ovarian steroid cell tumor not otherwise specified: A case report and literature review.

Authors:  Kai Li; Fufan Zhu; Jing Xiong; Fengying Liu
Journal:  Oncol Lett       Date:  2014-06-06       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.